CY1110690T1 - Ενωσεις 4-οξοκινολινης και χρησιμοποιηση αυτων ως αναστολεις της ενσωματασης του hiv - Google Patents

Ενωσεις 4-οξοκινολινης και χρησιμοποιηση αυτων ως αναστολεις της ενσωματασης του hiv

Info

Publication number
CY1110690T1
CY1110690T1 CY20091101301T CY091101301T CY1110690T1 CY 1110690 T1 CY1110690 T1 CY 1110690T1 CY 20091101301 T CY20091101301 T CY 20091101301T CY 091101301 T CY091101301 T CY 091101301T CY 1110690 T1 CY1110690 T1 CY 1110690T1
Authority
CY
Cyprus
Prior art keywords
hiv
compound
inhibitors
oxokinolin
inclusion
Prior art date
Application number
CY20091101301T
Other languages
Greek (el)
English (en)
Inventor
Motohide Satoh
Hiroshi Kawakami
Yoshiharu Itoh
Hisashi Shinkai
Takahisa Motomura
Hisateru Aramaki
Yuji Matsuzaki
Wataru Watanabe
Shuichi Wamaki
Original Assignee
Japan Tobacco, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32329647&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1110690(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Japan Tobacco, Inc. filed Critical Japan Tobacco, Inc.
Publication of CY1110690T1 publication Critical patent/CY1110690T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CY20091101301T 2002-11-20 2009-12-11 Ενωσεις 4-οξοκινολινης και χρησιμοποιηση αυτων ως αναστολεις της ενσωματασης του hiv CY1110690T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2002336843 2002-11-20
JP2003065807 2003-03-11
JP2003139616 2003-05-16
EP03811532A EP1564210B9 (en) 2002-11-20 2003-11-20 4-oxoquinoline compounds and utilization thereof as hiv integrase inhibitors

Publications (1)

Publication Number Publication Date
CY1110690T1 true CY1110690T1 (el) 2015-06-10

Family

ID=32329647

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20091101301T CY1110690T1 (el) 2002-11-20 2009-12-11 Ενωσεις 4-οξοκινολινης και χρησιμοποιηση αυτων ως αναστολεις της ενσωματασης του hiv
CY2013043C CY2013043I1 (el) 2002-11-20 2013-11-18 Ενωσεις 4-οξοκινολινης και χρησιμοποιηση αυτων ως αναστολεις της ενσωματασης του hiv

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY2013043C CY2013043I1 (el) 2002-11-20 2013-11-18 Ενωσεις 4-οξοκινολινης και χρησιμοποιηση αυτων ως αναστολεις της ενσωματασης του hiv

Country Status (31)

Country Link
US (6) US7176220B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (5) EP1564210B9 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR100665919B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR (2) AR042095A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE443048T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2003302029B8 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE (1) BE2013C063I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BRPI0306214B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2470365C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CY (2) CY1110690T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CZ (1) CZ2004764A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE60329318D1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK1564210T5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2329240T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (1) FR13C0061I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HUS1300066I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (2) IL162548A0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LT (1) LTPA2013018I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LU (1) LU92307I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MXPA04006553A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MY (1) MY136173A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (3) NO327098B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ533641A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PE (1) PE20040840A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT1564210E (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SI (1) SI1564210T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SK (1) SK2662004A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TR (1) TR200401663T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TWI248928B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2004046115A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA200404537B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20063848B (en) 2001-10-26 2006-06-12 Inst Di Richerche Di Biolog Moltcolare P Angeletti Spa N-substituted hydroxypyrimi-dinone carboxamide inhibitors of hiv integrase
CZ2004764A3 (cs) * 2002-11-20 2005-02-16 Japan Tobacco Inc 4-Oxochinolinová sloučenina a její použití jako inhibitoru HIV-integrázy
EP1730135B1 (en) 2004-03-10 2010-09-22 The United States of America, represented by the Secretary, Department of Health and Human Services Qiunolin-4-ones as inhibitors of retroviral integrase for the treatment of hiv, aids and aids related complex (arc)
US7531554B2 (en) * 2004-05-20 2009-05-12 Japan Tobacco Inc. 4-oxoquinoline compound and use thereof as HIV integrase inhibitor
MY134672A (en) * 2004-05-20 2007-12-31 Japan Tobacco Inc Stable crystal of 4-oxoquinoline compound
JP4629104B2 (ja) * 2004-05-21 2011-02-09 日本たばこ産業株式会社 ４−オキソキノリン誘導体および抗ｈｉｖ剤を含む併用剤
US7745459B2 (en) 2004-09-21 2010-06-29 Japan Tobacco Inc. Quinolizinone compound and use thereof as HIV integrase inhibitor
WO2006033422A1 (ja) * 2004-09-21 2006-03-30 Japan Tobacco Inc. キノリジノン化合物、およびそのｈｉｖインテグラーゼ阻害剤としての利用
UA87884C2 (uk) * 2004-12-03 2009-08-25 Мерк Энд Ко., Инк. Безводна кристалічна калієва сіль інгібітора віл-інтегрази
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
US20070032522A1 (en) * 2005-07-01 2007-02-08 Kumar Dange V Antiviral agents
WO2007063869A1 (ja) * 2005-11-30 2007-06-07 Japan Tobacco Inc. 高純度キノロン化合物の製造方法
JP4676536B2 (ja) * 2005-12-30 2011-04-27 ギリアド サイエンシズ， インコーポレイテッド Ｈｉｖインテグラーゼ阻害剤の薬物動態の改善方法
AU2013203476C1 (en) * 2005-12-30 2016-11-17 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors
US20090233964A1 (en) * 2005-12-30 2009-09-17 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors
WO2007089030A1 (en) 2006-02-01 2007-08-09 Japan Tobacco Inc. Use of 6-(3-chloro-2-fluorobenzyl)-1-[(2s)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or salt thereof for treating retrovirus infection
WO2007092802A1 (en) * 2006-02-09 2007-08-16 Boehringer Ingelheim International Gmbh Method for treating hiv infection through co-administration of tipranavir and gs 9137
CN101437801B (zh) * 2006-03-06 2013-02-06 日本烟草产业株式会社 制备4-氧代喹啉化合物的方法
EA017861B9 (ru) 2006-03-06 2014-05-30 Джапан Тобакко Инк. Способ получения 4-оксохинолинового соединения
PE20080697A1 (es) 2006-05-03 2008-08-05 Boehringer Ingelheim Int Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
TW200811153A (en) 2006-06-23 2008-03-01 Japan Tobacco Inc 6-(heterocyclyl-substituted benzyl)-4-oxoquinoline compound and use thereof as HIV integrase inhibitor
RU2399616C1 (ru) * 2006-06-23 2010-09-20 Джапан Тобакко Инк. Производное 6-(гетероциклзамещенный бензил)-4-оксохинолина и его применение в качестве ингибитора интегразы вич
EA025845B1 (ru) 2006-07-07 2017-02-28 Джилид Сайэнс, Инк. Модуляторы фармакокинетических свойств лекарственных средств
AU2007275805A1 (en) 2006-07-19 2008-01-24 University Of Georgia Research Foundation, Inc. Pyridinone diketo acids: Inhibitors of HIV replication in combination therapy
JP5221544B2 (ja) * 2006-09-12 2013-06-26 ギリアード サイエンシーズ， インコーポレイテッド インテグラーゼ阻害剤を調製するためのプロセスおよび中間体
ES2488922T3 (es) 2006-09-29 2014-09-01 Idenix Pharmaceuticals, Inc. Fosfoindoles enantiómeramente puros como inhibidores del HIV
WO2008077188A1 (en) 2006-12-22 2008-07-03 Avexa Limited Bicyclic pyrimidinones and uses thereof
EP2118082B1 (en) * 2007-02-23 2014-10-01 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
NZ582086A (en) * 2007-06-29 2012-07-27 Gilead Sciences Inc Therapeutic compositions and the use thereof
CN101743004A (zh) * 2007-06-29 2010-06-16 吉里德科学公司 治疗用组合物及其用途
CL2008002427A1 (es) 2007-08-16 2009-09-11 Boehringer Ingelheim Int Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2.
AR068403A1 (es) * 2007-09-11 2009-11-18 Gilead Sciences Inc Proceso e intermediarios para la preparacion de inhibidores de integrasa
MX2010002679A (es) * 2007-09-12 2010-03-29 Concert Pharmaceuticals Inc Derivados de 4-oxoquinolina deuterados para el tratamiento de la infeccion por el virus de inmunodeficiencia humana.
US8377960B2 (en) * 2007-11-15 2013-02-19 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
EP2220046B1 (en) 2007-11-16 2014-06-18 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
EP2234608A2 (en) 2007-12-11 2010-10-06 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
US20110166123A1 (en) * 2008-01-07 2011-07-07 Aardea Biosciences, Inc. Novel compositions and methods of use
KR101784647B1 (ko) 2008-05-02 2017-10-11 길리애드 사이언시즈, 인코포레이티드 제약 제제의 가공성 향상을 위한 고체 담체 입자의 용도
WO2010073078A2 (en) * 2008-12-22 2010-07-01 Orchid Research Laboratories Ltd. Heterocyclic compounds as hdac inhibitors
SI2393485T1 (sl) 2009-02-06 2015-10-30 Gilead Sciences, Inc. Dvoslojne tablete, ki vsebujejo elvitegravir, cobicistat, emtricitabin in tenofovir
CN104906582A (zh) 2009-02-13 2015-09-16 勃林格殷格翰国际有限公司 包含sglt2抑制剂、dpp-iv抑制剂和任选的另一种抗糖尿病药的药物组合物及其用途
WO2010137032A2 (en) 2009-05-14 2010-12-02 Matrix Laboratories Ltd. Novel polymorphic forms of elvitegravir and its pharmaceutically acceptable salts
WO2011004389A2 (en) 2009-06-18 2011-01-13 Matrix Laboratories Ltd An improved process for the preparation of elvitegravir
US20120220571A1 (en) * 2009-08-26 2012-08-30 Wai John S Hiv integrase inhibitors
BR112012007085B8 (pt) 2009-09-30 2021-05-25 Boehringer Ingelheim Int processos para a preparação de derivados de benzil-benzeno substituídos com glicopiranosila
CN102549005B (zh) 2009-09-30 2015-08-26 贝林格尔.英格海姆国际有限公司 1-氯-4-(β-D-吡喃葡萄糖-1-基)-2-[4-((S)-四氢呋喃-3-基氧基)-苄基]-苯的晶型的制备方法
UY32919A (es) 2009-10-02 2011-04-29 Boehringer Ingelheim Int Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, mé todos para su tratamiento y sus usos
CA2777664C (en) 2009-10-13 2014-06-10 Johannes Wilhelmus J. Thuring Macrocyclic integrase inhibitors
CN102753526B (zh) 2009-12-07 2014-11-26 佐治亚大学研究基金会 吡啶酮羟基环戊基羧酰胺：具有治疗用途的hiv 整合酶抑制剂
WO2011121105A1 (en) 2010-04-02 2011-10-06 Tibotec Pharmaceuticals Macrocyclic integrase inhibitors
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
PE20130385A1 (es) 2010-07-02 2013-03-30 Gilead Sciences Inc Derivados del acido naft-2-ilacetico para tratar el sida
CN103209963A (zh) 2010-07-02 2013-07-17 吉里德科学公司 作为hiv抗病毒化合物的2-喹啉基-乙酸衍生物
AR085689A1 (es) 2011-03-07 2013-10-23 Boehringer Ingelheim Int Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2
CN105712948A (zh) 2011-04-21 2016-06-29 吉利德科学公司 苯并噻唑化合物及其药学上的应用
US9284323B2 (en) 2012-01-04 2016-03-15 Gilead Sciences, Inc. Naphthalene acetic acid derivatives against HIV infection
WO2013103724A1 (en) 2012-01-04 2013-07-11 Gilead Sciences, Inc. 2- (tert - butoxy) -2- (7 -methylquinolin- 6 - yl) acetic acid derivatives for treating aids
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US9192617B2 (en) 2012-03-20 2015-11-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
UY34750A (es) 2012-04-20 2013-11-29 Gilead Sciences Inc ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?.
PT2880017T (pt) 2012-08-03 2016-12-14 Gilead Sciences Inc Processo e intermediários para preparar inibidores da integrase
CZ304984B6 (cs) 2012-10-12 2015-03-11 Zentiva, K.S. Zlepšený způsob výroby a nové intermediáty syntézy elvitegraviru
CZ304983B6 (cs) 2012-10-12 2015-03-11 Zentiva, K.S. Způsob výroby a nové intermediáty syntézy elvitegraviru
PT3608325T (pt) 2012-12-21 2022-10-17 Gilead Sciences Inc Compostos carbamoílpiridona policíclicos e sua utilização farmacêutica
AU2013370517B2 (en) 2012-12-26 2017-04-06 Société des Produits Nestlé S.A. Low density coated animal litter compositions
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
HK1213818A1 (zh) 2013-04-05 2016-07-15 勃林格殷格翰国际有限公司 依帕列净的治疗用途
PT2981271T (pt) 2013-04-05 2019-02-19 Boehringer Ingelheim Int Utilizações terapêuticas de empagliflozina
PL2986304T3 (pl) 2013-04-18 2022-05-02 Boehringer Ingelheim International Gmbh Kompozycja farmaceutyczna, sposoby leczenia i jej zastosowania
CZ307255B6 (cs) 2013-07-11 2018-05-02 Zentiva, K.S. Nový způsob přípravy elvitegraviru
NO2865735T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2013-07-12 2018-07-21
JP6411491B2 (ja) 2013-07-12 2018-10-24 ギリアード サイエンシス インコーポレーテッド 多環式カルバモイルピリドン化合物およびｈｉｖ感染症を処置するためのその使用
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
NO2717902T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2014-06-20 2018-06-23
TWI677489B (zh) 2014-06-20 2019-11-21 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
JP2017538689A (ja) 2014-11-17 2017-12-28 ニーロジョン セラピューティクス インコーポレイテッドＮｉｒｏｇｙｏｎｅ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． モノカルボン酸輸送修飾薬およびその使用
TWI738321B (zh) 2014-12-23 2021-09-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
JP6402259B2 (ja) 2015-04-02 2018-10-10 ギリアード サイエンシーズ， インコーポレイテッド 多環式カルバモイルピリドン化合物およびそれらの薬学的使用
WO2016193997A2 (en) * 2015-06-03 2016-12-08 Msn Laboratories Private Limited Process for the preparation of 6-(3-chloro-2-fluorobenzyl)-1-[(2s)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid and pharmaceutically acceptable salts thereof
ES2925000T3 (es) 2015-10-23 2022-10-13 Nestle Sa Arenas higiénicas para mascotas de baja densidad y métodos de elaboración de tales arenas higiénicas para mascotas
RU2654062C2 (ru) * 2016-07-14 2018-05-16 Государственное бюджетное образовательное учреждение высшего профессионального образования "Волгоградский государственный медицинский университет" Министерства здравоохранения Российской Федерации Производные хиназолин-4(3н)-она, ингибирующие натрий-водородный обмен
JP7625363B2 (ja) 2016-11-10 2025-02-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 医薬組成物、治療方法及びその使用

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3472859A (en) * 1966-11-01 1969-10-14 Sterling Drug Inc 1-alkyl-1,4-dihydro-4-oxo-3 quinoline-carboxylic acids and esters
JPS4826772A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1971-08-11 1973-04-09
DE3501247A1 (de) 1985-01-16 1986-07-17 Bayer Ag, 5090 Leverkusen Aminoacrylsaeure-derivate
US5591744A (en) * 1987-04-16 1997-01-07 Otsuka Pharmaceutical Company, Limited Benzoheterocyclic compounds
EP0319906A3 (en) * 1987-12-11 1990-05-02 Dainippon Pharmaceutical Co., Ltd. Novel quinoline derivatives, processes for preparation thereof and antibacterial agent containing them
US4920120A (en) * 1988-01-25 1990-04-24 Warner-Lambert Company Antibacterial agents
DE3934082A1 (de) * 1989-10-12 1991-04-18 Bayer Ag Chinoloncarbonsaeurederivate, verfahren zu ihrer herstellung sowie ihre verwendung als antivirale mittel
DE4015299A1 (de) 1990-05-12 1991-11-14 Bayer Ag Verfahren zur herstellung von 3-amino-2-(het)-aroyl-acrylsaeurederivaten
IL100555A (en) 1991-02-07 2000-08-31 Hoechst Marion Roussel Inc N-substituted quinoline derivatives their preparation their use for the preparation of medicaments and the pharmaceutical compositions containing them
NO304832B1 (no) 1992-05-27 1999-02-22 Ube Industries Aminokinolonderivater samt middel mot HIV
JP2993316B2 (ja) 1992-05-27 1999-12-20 宇部興産株式会社 アリール基又は複素芳香環基置換アミノキノロン誘導体及びエイズ治療剤
JPH06199635A (ja) 1992-12-28 1994-07-19 Kanebo Ltd 化粧料
JPH06199835A (ja) 1993-01-08 1994-07-19 Hokuriku Seiyaku Co Ltd ８−ジフルオロメトキシキノリン−３−カルボン酸誘導体
JPH06271568A (ja) 1993-03-22 1994-09-27 Hokuriku Seiyaku Co Ltd ７−フェニルピペラジニルキノリン−３−カルボン酸誘導体
WO1995029891A1 (fr) 1994-04-28 1995-11-09 Yamanouchi Pharmaceutical Co., Ltd. Derive de n-(3-pyrrolidinyl)benzamide
EP0773214A4 (en) 1994-07-18 1998-04-15 Ube Industries TRIFLUOROMETHYLQUINOLEINECARBOXYLIC ACID
JP2930539B2 (ja) 1994-07-18 1999-08-03 三共株式会社 トリフルオロメチルキノリンカルボン酸誘導体
JPH08183776A (ja) 1994-12-28 1996-07-16 Hideaki Yamaguchi 金属の表面保護剤ならびにそれを用いた製造方法
US6303611B1 (en) * 1996-03-08 2001-10-16 Adolor Corporation Kappa agonist compounds and pharmaceutical formulations thereof
JP4121151B2 (ja) 1996-04-12 2008-07-23 アメリカ合衆国 抗新生物薬および抗レトロウイルス薬として有用なアクリドンから誘導された化合物
US6287550B1 (en) * 1996-12-17 2001-09-11 The Procter & Gamble Company Animal care system and litter with reduced malodor impression
US5989451A (en) 1997-02-07 1999-11-23 Queen's University At Kingston Compounds and methods for doping liquid crystal hosts
FR2761687B1 (fr) 1997-04-08 2000-09-15 Centre Nat Rech Scient Derives de quinoleines, possedant notamment des proprietes antivirales, leurs preparations et leurs applications biologiques
JP3776203B2 (ja) 1997-05-13 2006-05-17 第一製薬株式会社 Ｉｃａｍ−１産生阻害剤
KR20010013377A (ko) * 1997-06-04 2001-02-26 데이비드 엠 모이어 마일드한 잔류성 항균 조성물
TW527355B (en) 1997-07-02 2003-04-11 Bristol Myers Squibb Co Inhibitors of farnesyl protein transferase
JPH1184556A (ja) 1997-09-08 1999-03-26 Konica Corp ハロゲン化銀乳剤、該乳剤を用いる感光材料の処理方法及び撮影方法
GB9721964D0 (en) 1997-10-16 1997-12-17 Pfizer Ltd Isoquinolines
GB9807903D0 (en) 1998-04-14 1998-06-10 Smithkline Beecham Plc Novel compounds
US6399629B1 (en) * 1998-06-01 2002-06-04 Microcide Pharmaceuticals, Inc. Efflux pump inhibitors
US6248736B1 (en) 1999-01-08 2001-06-19 Pharmacia & Upjohn Company 4-oxo-1,4-dihydro-3-quinolinecarboxamides as antiviral agents
US6248739B1 (en) 1999-01-08 2001-06-19 Pharmacia & Upjohn Company Quinolinecarboxamides as antiviral agents
FR2795726A1 (fr) 1999-06-30 2001-01-05 Aventis Cropscience Sa Nouveaux pyrazoles fongicides
DE19950898A1 (de) * 1999-10-22 2001-04-26 Aventis Pharma Gmbh Heterocyclisch substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
PE20011349A1 (es) 2000-06-16 2002-01-19 Upjohn Co 1-aril-4-oxo-1,4-dihidro-3-quinolincarboxamidas como agentes antivirales
US6730682B2 (en) 2000-07-12 2004-05-04 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
US6559145B2 (en) * 2000-07-12 2003-05-06 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
EP1326610B1 (en) 2000-10-12 2006-11-15 Merck & Co., Inc. Aza-and polyaza-naphthalenyl carboxamides useful as hiv integrase inhibitors
CA2425067A1 (en) 2000-10-12 2002-05-10 Merck & Co., Inc. Aza-and polyaza-naphthalenyl ketones useful as hiv integrase inhibitors
AU2905702A (en) * 2000-12-14 2002-06-24 Procter & Gamble Cyclization process step in the making of quinolones and naphthyridines
US20040198716A1 (en) 2001-02-05 2004-10-07 Dorit Arad Cysteine protease inhimbitors
BR0207809A (pt) 2001-03-01 2004-03-09 Shionogi & Co Compostos heteroarila contendo nitrogênio possuindo atividade inibidora contra integrase de hiv
JP4518302B2 (ja) 2001-03-19 2010-08-04 日本化薬株式会社 水溶性ジスアゾ化合物、水性ブラックインク組成物および着色体
JP2002293745A (ja) 2001-03-29 2002-10-09 St Marianna Univ School Of Medicine 慢性関節リウマチ治療剤
JP3980842B2 (ja) 2001-05-11 2007-09-26 バブコック日立株式会社 アンモニア含有排水の浄化装置および浄化方法
JP2003065807A (ja) 2001-08-29 2003-03-05 Mitsubishi Electric Corp プロセスデータのトレンド表示方法および装置
JP3913037B2 (ja) 2001-10-30 2007-05-09 三菱電機株式会社 赤外線検出器
TW200300349A (en) 2001-11-19 2003-06-01 Sankyo Co A 4-oxoqinoline derivative
CZ2004764A3 (cs) * 2002-11-20 2005-02-16 Japan Tobacco Inc 4-Oxochinolinová sloučenina a její použití jako inhibitoru HIV-integrázy
JP2004253231A (ja) 2003-02-20 2004-09-09 Pioneer Electronic Corp プラズマディスプレイパネル
MY134672A (en) * 2004-05-20 2007-12-31 Japan Tobacco Inc Stable crystal of 4-oxoquinoline compound
US7531554B2 (en) * 2004-05-20 2009-05-12 Japan Tobacco Inc. 4-oxoquinoline compound and use thereof as HIV integrase inhibitor
JP4629104B2 (ja) * 2004-05-21 2011-02-09 日本たばこ産業株式会社 ４−オキソキノリン誘導体および抗ｈｉｖ剤を含む併用剤
EA017861B9 (ru) 2006-03-06 2014-05-30 Джапан Тобакко Инк. Способ получения 4-оксохинолинового соединения
CN101437801B (zh) 2006-03-06 2013-02-06 日本烟草产业株式会社 制备4-氧代喹啉化合物的方法
TW200811153A (en) * 2006-06-23 2008-03-01 Japan Tobacco Inc 6-(heterocyclyl-substituted benzyl)-4-oxoquinoline compound and use thereof as HIV integrase inhibitor
JP5221544B2 (ja) 2006-09-12 2013-06-26 ギリアード サイエンシーズ， インコーポレイテッド インテグラーゼ阻害剤を調製するためのプロセスおよび中間体
AR068403A1 (es) 2007-09-11 2009-11-18 Gilead Sciences Inc Proceso e intermediarios para la preparacion de inhibidores de integrasa
MX2010002679A (es) * 2007-09-12 2010-03-29 Concert Pharmaceuticals Inc Derivados de 4-oxoquinolina deuterados para el tratamiento de la infeccion por el virus de inmunodeficiencia humana.
US20110166123A1 (en) 2008-01-07 2011-07-07 Aardea Biosciences, Inc. Novel compositions and methods of use
SI23420A (sl) 2010-07-22 2012-01-31 Institut "Jožef Stefan" Kostni vsadki z večslojno prevleko in postopek njihove priprave
US11347056B2 (en) 2018-08-22 2022-05-31 Microsoft Technology Licensing, Llc Foveated color correction to improve color uniformity of head-mounted displays
JP7397852B2 (ja) 2018-08-23 2023-12-13 エルジー イノテック カンパニー リミテッド センシング装置
WO2020040561A1 (ko) 2018-08-24 2020-02-27 한온시스템 주식회사 차량용 공조장치

Also Published As

Publication number Publication date
HUS1300066I1 (hu) 2016-11-28
BRPI0306214B8 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2021-05-25
CZ2004764A3 (cs) 2005-02-16
AR042095A1 (es) 2005-06-08
US20150174117A1 (en) 2015-06-25
AU2003302029B2 (en) 2006-08-10
ES2329240T3 (es) 2009-11-24
HK1080852A1 (en) 2006-05-04
NO20043004L (no) 2004-07-14
US20050239819A1 (en) 2005-10-27
BE2013C063I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2023-03-07
LU92307I2 (fr) 2014-01-13
IL162548A0 (en) 2005-11-20
US7176220B2 (en) 2007-02-13
FR13C0061I2 (fr) 2014-11-07
KR100665919B1 (ko) 2007-03-08
NO2013015I1 (no) 2013-11-07
EP1564210A1 (en) 2005-08-17
NO327098B1 (no) 2009-04-20
EP4059923A1 (en) 2022-09-21
LTPA2013018I1 (lt) 2022-09-12
DE60329318D1 (de) 2009-10-29
KR20040081443A (ko) 2004-09-21
US8232401B2 (en) 2012-07-31
PE20040840A1 (es) 2004-12-30
FR13C0061I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2013-12-20
TW200412339A (en) 2004-07-16
NZ533641A (en) 2006-07-28
SI1564210T1 (sl) 2010-01-29
AR087046A2 (es) 2014-02-12
US20060217413A1 (en) 2006-09-28
US20130172344A1 (en) 2013-07-04
US20200101061A1 (en) 2020-04-02
TR200401663T1 (tr) 2005-04-21
EP1564210A4 (en) 2007-08-22
EP3406596A1 (en) 2018-11-28
BRPI0306214B1 (pt) 2017-08-08
SK2662004A3 (sk) 2005-06-02
US20230190730A1 (en) 2023-06-22
EP1564210B1 (en) 2009-09-16
CA2470365A1 (en) 2004-06-03
IL162548A (en) 2008-12-29
EP1564210B9 (en) 2010-03-31
CY2013043I1 (el) 2020-05-29
AU2003302029B8 (en) 2006-08-17
LU92307I9 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2019-01-17
EP2272516A3 (en) 2011-03-16
TWI248928B (en) 2006-02-11
DK1564210T3 (da) 2009-11-16
CA2470365C (en) 2011-05-17
MXPA04006553A (es) 2004-10-04
EP2161258A2 (en) 2010-03-10
PT1564210E (pt) 2009-10-26
ATE443048T1 (de) 2009-10-15
WO2004046115A1 (ja) 2004-06-03
DK1564210T5 (da) 2010-05-03
AU2003302029A1 (en) 2004-06-15
BR0306214A (pt) 2004-08-24
ZA200404537B (en) 2005-08-31
MY136173A (en) 2008-08-29
NO2022032I1 (no) 2022-07-22
NO2013015I2 (no) 2014-06-02
EP2272516A2 (en) 2011-01-12
EP2161258A3 (en) 2010-04-07

Similar Documents

Publication Publication Date Title
CY1110690T1 (el) Ενωσεις 4-οξοκινολινης και χρησιμοποιηση αυτων ως αναστολεις της ενσωματασης του hiv
TW200510425A (en) Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
EA200400585A1 (ru) N-замещённые гидроксипиримидинон-карбоксамидные ингибиторы вич интегразы
BR0316771A (pt) Compostos para o tratamento ou a prevenção de infecções por flavivirus, uso de um composto e composição farmacêutica
CY1106606T1 (el) Διϋδροξυπυριμιδινο καρβοξαμιδια αναστολεις της ιντεγκρασης του hiv
NO20032488D0 (no) Orto-substituerte nitrogen-inneholdende bisarylforbindelser anvendt som kaliumkanalinhibitorer
DK0951474T3 (da) Nye cyclosporinderivater, deres fremstilling og farmaceutiske præparater deraf
ES2178037T3 (es) Derivados de ciclosporina, su preparacion y las composiciones farmaceuticas que los contienen.
CY1108036T1 (el) Κυτταρικη συσσωρευση φωσφονικων αναλογων ενωσεων αναστολεα πρωτεασης του ιου ανοσολογικης ανεπαρκειας του ανθρωπου (hiv) και οι ενωσεις ως τετοιες
ATE504294T1 (de) Nichtnukleosidische reverse-transkriptase-hemmer
ATE373005T1 (de) Thienopyrrole als antivirale mittel
NO20090322L (no) 6-(heterosykel-substituert benzyl)-4-oksoquinolin forbindelse samt anvendelse av det samme som IIIV integrave inhibitor
MXPA06000418A (es) Derivados de ariltiourea sustituida utiles como inhibidores de duplicacion viral.
SE0101932D0 (sv) Pharmaceutical combinations
DE69909747D1 (de) Pharmazeutische zusammensetzung, enthaltend peg-asparaginase, für die behandlung von hiv infektionen
CO4130200A1 (es) Inhibidores de proteasa del hiv utiles en el tratamiento del sida
EA199700150A1 (ru) КОМБИНИРОВАННОЕ ЛЕЧЕНИЕ ПО ПОВОДУ ВИЧ ИНФЕКЦИИ С ИСПОЛЬЗОВАНИЕМ ИНГИБИТОРА ПРОТЕАЗЫ ВИЧ ИНДИНАВИРА И ИНГИБИТОРА ОБРАТНОЙ ТРАНСКРИПТАЗЫ 3TC, НЕОБЯЗАТЕЛЬНО СОВМЕСТНО С AZT, ddI ИЛИ ddC
DK1451182T3 (da) Dimere forbindelser og deres anvendelse som antivirale midler
WO2003016266A1 (en) β-KETOAMIDE COMPOUNDS AND MEDICINAL USE THEREOF
DK1411956T3 (da) Anvendelse af oversulfaterede polysaccharider som inhibitorer af HIV
EA200000513A1 (ru) Комбинированная терапия для лечения спид
GEP20247701B (en) Pyrimidine-based bicycles as antiviral agents for the treatment and prevention of hiv infection
DE60104530D1 (de) Diphenyl ketoaldehyde-derivate mit wirkung gegen hiv
CY1106129T1 (el) Κιταλοπραμη για την αγωγη της υψηλης πιεσεως του αιματος
MX9700036A (es) Combinacion de compuestos, uso en la preparacion de composiciones para tratar infeccion por el vir s de inmunodeficiencia humana, y composiciones obtenidas.